When Dave Rosa looks at Intuitive Surgical’s trajectory entering 2026, he does not frame it as a breakthrough moment. Instead, he describes it as the natural evolution of a platform that has matured into infrastructure. Rosa spoke at the 44th annual J.P. Morgan Healthcare Conference in January.
For more than 30 years, Intuitive has helped define robotic-assisted surgery. What began as an emerging technology has become embedded in operating rooms around the world. In the fourth quarter of 2025, the company crossed a defining milestone — 20 million cumulative procedures performed globally on its platforms. That number represents 20 million individual clinical decisions in which surgeons chose robotics as part of patient care.
“Twenty million times, a physician chose one of our systems to treat a patient,” Rosa said. “That reflects durability. It reflects value. And it reflects the work our teams have done to support customers over decades.”
In 2025 alone, approximately 3.2 million procedures were performed across Intuitive’s portfolio. Revenue grew to roughly $10 billion, representing approximately 21 percent growth year over year. Fourth-quarter da Vinci procedure growth reached approximately 17 percent, with total procedure growth around 18 percent. Installed base expansion remained strong, with roughly 1,900 systems placed during the year, bringing the global installed base to more than 12,000 systems.
But Rosa views the headline metrics as outputs — not the core thesis. The deeper story, he believes, is that robotic surgery has entered its next phase. Robotics is no longer novel. It is expected. The differentiator now lies in ecosystem depth — data, digital integration, training infrastructure, imaging capability, and global execution.
The Framework That Guides the Strategy
At the center of Intuitive’s operating philosophy remains what Rosa calls the quintuple aim — improving outcomes, lowering total cost of care, expanding access, enhancing patient and care-team experience, and supporting clinician well-being.
That framework serves as more than a mission statement. It shapes investment decisions and platform priorities. Hospitals increasingly evaluate robotic programs not simply as capital equipment purchases, but as long-term strategic assets. They assess utilization, workflow integration, staffing efficiency, training support, clinical evidence, and financial sustainability.
In that environment, scale and execution matter. Two decades ago, approximately 17 percent of Intuitive’s procedures were performed outside the United States. Today, roughly 35 percent occur internationally. Markets such as India, Korea, Canada, and distributor regions delivered strong performance in 2025. Japan experienced capital replacement pressures during the year. China remains a competitive market with domestic robotic entrants increasing intensity. Yet the broader international trend underscores that robotic surgery is no longer geographically concentrated — it is global.
The installed base expansion reinforces that reach. With more than 12,000 systems worldwide, Intuitive supports a vast network of surgeons, care teams, hospital administrators, and researchers. That network generates clinical publications, develops training pathways, and contributes to the expanding body of evidence around robotic surgery.
da Vinci 5 — Engineering for the Next Decade
The most visible symbol of Intuitive’s platform evolution in 2025 was the broad launch of da Vinci 5.
Cleared in the United States, Europe, Japan, and Korea, da Vinci 5 has already been used in more than 270,000 procedures and installed in over 1,200 locations. More than 10,000 surgeons have used the platform since launch.
One early indicator has drawn attention — utilization in the United States is running approximately 11 percent higher than da Vinci Xi. For Rosa, that statistic validates design intent.
“We wanted to build in more surgeon autonomy and greater efficiency,” he said. “Higher utilization tells us we are moving in the right direction.”
Utilization is a critical lever in robotic program economics. Hospitals evaluate not only acquisition cost but case volume per system, throughput, and per-procedure economics. A platform that supports increased utilization strengthens return on investment and enables broader patient access.
The da Vinci 5 incorporates force feedback and Force Gauge technologies, providing quantifiable data about tissue interaction — a capability long requested by surgeons operating in minimally invasive environments. User interface refinements and console improvements enhance ergonomics and workflow. Instrument additions, including the Curve vessel sealer, broaden versatility.
The development roadmap continues to expand. Molecular imaging initiatives aim to improve ureter visualization and reduce positive margins in prostate cancer surgery. Hyperspectral imaging under development is designed to display tissue perfusion and oxygenation in real time, potentially influencing intraoperative decisions. An articulated wristed multi-fire clip applier remains in development, addressing surgeon demand for enhanced dexterity in anatomically challenging procedures.
Rather than viewing da Vinci 5 as a discrete launch event, Rosa describes it as a foundation for iterative advancement.
“When we launch a system, we commit to making it better over time,” he said. “That’s part of how we build durable platforms.”
Digital as the Differentiator
If robotics defined Intuitive’s first era, data may define its second. Today, more than 1,000 surgical cases per day flow into the company’s digital ecosystem. That expanding dataset supports Case Insights, simulation alignment, and performance benchmarking delivered through My Intuitive.
The roadmap follows a progression. First, capture structured surgical data. Second, analyze patterns and generate insights. Third, deliver guidance in ways that are actionable for surgeons and care teams.
Telepresence tools already enable collaboration and mentoring across institutions. Surgeons can share case data and discuss techniques remotely. Future capabilities include telesurgery integration and augmented dexterity features — such as protected anatomical zones designed to safeguard critical structures.
Artificial intelligence (AI) already plays a role within the Ion platform, where machine learning supports CT segmentation and navigation. Over time, AI is expected to inform workflow optimization, performance modeling, and intraoperative guidance across the portfolio.
The installed base provides scale. With more than 12,000 systems generating data, Intuitive’s digital infrastructure rests on a large and growing foundation.
Expanding the Procedure Horizon
Intuitive estimates that approximately 23 million soft tissue procedures occur globally each year. Roughly 20 million could potentially be performed using minimally invasive techniques. Approximately 9 million represent current line-of-sight opportunities supported by regulatory clearance, reimbursement alignment, and economic feasibility.
Growth comes from expanding penetration within the 9 million, broadening toward the 20 million through evidence and market access efforts, and developing entirely new platforms beyond soft tissue surgery.
The single-port platform illustrates this progression. In 2025, SP delivered approximately 87 percent procedure growth, 39 percent installed base growth, and 29 percent utilization growth. Expanded indications, including nipple-sparing mastectomy in the United States, and instrument additions such as the SureForm stapler have broadened its applicability.
Outside the United States, benign procedures represent a significant opportunity. In many regions, the clinical value proposition is well understood. The gating factor is often reimbursement structure and capital economics. Portfolio segmentation, including refurbished Xi systems, allows Intuitive to address cost-sensitive markets without fragmenting the broader ecosystem.
Ion — Transforming Lung Care Pathways
Ion, Intuitive’s robotic bronchoscopy platform, represents the company’s first major expansion beyond traditional soft tissue surgery. Approximately 140,000 procedures were performed on Ion in 2025, reflecting 51 percent year-over-year growth. Installed base and utilization trends indicate increasing physician confidence.
The opportunity extends beyond incremental growth. Lung cancer survival remains approximately 25 percent at five years overall yet exceeds 90 percent when detected at stage 1A. Today, diagnostic pathways from nodule detection to treatment can exceed six months.
Intuitive aims to compress that timeline to under one month by integrating rapid on-site evaluation technologies, endobronchial ultrasound staging, and future focal therapy capabilities. Early adopter data from institutions pairing Ion with advanced imaging suggest increased early-stage detection rates.
The current line-of-sight lung biopsy opportunity is estimated at approximately 700,000 procedures annually within a broader 1.5 million-procedure biopsy market. As development progresses in treatment and benign lung disease, that opportunity could expand further.
For Rosa, Ion represents a proof point — that the company’s capabilities in robotics, imaging, and data integration can be applied to entirely new disease pathways.
Competing in a Maturing Market
Robotic surgery is no longer uncontested territory. Competitive intensity has increased, particularly in soft tissue applications. Domestic competitors in certain markets have introduced new systems. Regulatory filings from additional entrants continue.
Rosa frames differentiation through ecosystem depth rather than feature comparison.
“Hospitals are evaluating more than hardware,” he said. “They are evaluating training, data, reliability, service, and the long-term partnership.”
With more than 12,000 installed systems, tens of thousands of trained surgeons, and a digital infrastructure generating structured case data daily, Intuitive benefits from scale. Thousands of engineers continue to iterate across hardware, imaging, and software layers. Sustained research and development investment supports both near-term enhancements and long-term platform expansion.
Switching costs, training familiarity, and ecosystem integration create resilience in a maturing category.
Operational Discipline at Scale
Scaling high-precision robotic systems globally requires operational rigor. Manufacturing quality, supply chain resilience, and service responsiveness become increasingly critical as installed base grows.
Rosa emphasizes that reliability is not optional. Hospitals depend on uptime and service consistency. Meeting those expectations demands continued investment in manufacturing capacity, quality systems, and operational infrastructure.
As robotic surgery becomes embedded in clinical pathways, reliability becomes as important as innovation.
Looking Forward
Entering 2026, Intuitive’s priorities remain clear — expand da Vinci 5 globally, continue SP and Ion adoption, deepen digital integration, and advance early-stage research and development aimed at new disease states.
Procedure growth drivers remain anchored in general surgery in the United States and expanding specialties internationally. The digital roadmap continues to unfold. Ion’s clinical pathway ambitions extend beyond biopsy.
After three decades, Intuitive appears less defined by a single robotic device and more by a comprehensive surgical ecosystem — integrating robotics, data, imaging, and artificial intelligence.
The first 20 million procedures established robotic-assisted surgery as a durable standard. The next chapter may determine how digital intelligence and global scale elevate that standard further — expanding precision, accelerating diagnosis, and extending minimally invasive care to millions more patients worldwide.
This article was written by Sherrie Trigg, Editor and Director of Content, Medical Design Briefs. She can be reached at
